| Identification | Back Directory | [Name]
4H-1-Benzopyran-4-one, 3-(4-bromophenyl)-7-[4-[[2-(dimethylamino)ethyl]methylamino]butoxy]- | [CAS]
2939087-00-8 | [Synonyms]
4H-1-Benzopyran-4-one, 3-(4-bromophenyl)-7-[4-[[2-(dimethylamino)ethyl]methylamino]butoxy]- | [Molecular Formula]
C24H29BrN2O3 | [MOL File]
2939087-00-8.mol | [Molecular Weight]
473.4 |
| Chemical Properties | Back Directory | [Boiling point ]
567.1±50.0 °C(predicted) | [density ]
1.293±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | [pka]
8.55±0.38(predicted) |
| Hazard Information | Back Directory | [Uses]
DBI-2 is an AMPK activator targeting mitochondrial complex I. DBI-2 disrupts the OXPHOS process, and reduces ATP generation in mitochondria. DBI-2 inhibits the proliferation of colorectal cancer (CRC) cells[1]. | [in vivo]
DBI-2 (40 mg/kg; ip; for 12 days) inhibits tumor growth in olorectal cancer (CRC) xenograft mouse models[1].
| Animal Model: | RAG1?/? γc? mice injected with S174T cells[1] | | Dosage: | 40 mg/kg | | Administration: | Intraperitoneal administration; for 12 days | | Result: | Suppressed of tumor growth. |
| [References]
[1] Lichao Guo, et al. Inhibition of Carbohydrate Metabolism Potentiated by the Therapeutic Effects of Oxidative Phosphorylation Inhibitors in Colon Cancer Cells. Cancers (Basel). 2024 Apr 2;16(7):1399. DOI:10.3390/cancers16071399 |
|
|